Top

Cost Effectiveness and Resource Allocation

Published in:

Open Access 01-12-2023 | Editorial

Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.

Authors: Makoto Kosaka, Akihiko Ozaki, Yudai Kaneda, Hiroaki Saito, Erika Yamashita, Anju Murayama, Hanano Mamada, Tetsuya Tanimoto, Mihajlo Jakovljevic

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2023

Excerpt

Japan established a national health insurance scheme in 1961, and thanks to this, all the Japanese population have equal access to decent medical care by paying only 10–30% of the medical cost from their own pocket basically, depending on the person's age [1]. An overlooked consequence was ever-increasing healthcare costs. With the advancement of medical technology and a fast-aging society, Japan’s healthcare cost has kept rising, exceeding 44 trillion JPY in 2019, which calls for an overhaul of its health insurance scheme [2]. However, the Japanese government failed to offer a fundamental solution and instead took a temporary measure in 2015 to encourage the use of generic drugs. …

https://japanhpn.org/en/section-6-2/.

https://gemmed.ghc-j.com/?p=44190.

Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan—key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):181–94. https://doi.org/10.1586/14737167.2014.881254.CrossRefPubMed

https://www.mixonline.jp/tabid55.html?artid=70975.

https://answers.tenavi.com/pharmanews/18470/#:~:text=%E4%BA%8B%E6%A5%AD%E3%82%92%E6%A8%A1%E7%B4%A2-,%E6%97%A5%E5%8C%BB%E5%B7%A514%25%E5%A2%97%E5%8F%8E,%E5%86%86%EF%BC%885.0%25%E5%A2%97%EF%BC%89%E3%80%82.

NHK, Nippon Hoso Kyokai, Japan. Generic drug manufacturers face a series of problems, some of which are hindering the availability of generic drugs. https://www3.nhk.or.jp/news/html/20210805/k10013182521000.html. Accessed August 6, 2021.

Ministry of Health, Labour and Welfare, Japan. Minutes of the 6th Meeting of the Conference of Stakeholders on Measures to Ensure the Stability of Ethical Drugs. https://www.mhlw.go.jp/stf/newpage_25308.html. Accessed May 27, 2022.

Jakovljevic M, Sugahara T, Timofeyev Y, Rancic N. Predictors of (in) efficiencies of healthcare expenditure among the leading Asian economies—comparison of OECD and non-OECD nations. Risk Manag Healthc Policy. 2020;13:2261.CrossRefPubMedPubMedCentral

Mori J, Kenichi H, Tetsuya T, Tomoko M, Masahiro K. Drug shortages after the Eastern Japan Earthquake: experiences in a tertiary referral center. Drug Inf J. 2012;46(5):607–10.CrossRef

10.

Jakovljevic M. Therapeutic innovations: the future of health economics and outcomes research—increasing role of the Asia-Pacific. J Med Econ. 2021;24(Sup 1):1–2.

11.

Jakovljevic M, Wu W, Merrick J, Cerda A, Varjacic M, Sugahara T. Asian innovation in pharmaceutical and medical device industry—beyond tomorrow. J Med Econ. 2021;24(Sup 1):42–50.CrossRefPubMed

12.

Umemura M. Crisis and change in the system of innovation: the Japanese pharmaceutical industry during the lost decades, 1990–2010. Bus Hist. 2014;56(5):816–44.CrossRef

13.

Ogura S, Jakovljevic M. Health financing constrained by population aging—an opportunity to learn from Japanese experience. Serb J Exp Clin Res. 2014;15(4):175–81.CrossRef

14.

Iizuka T, Kensuke K. The generic drug market in Japan: will it finally take off? Health Econ Policy Law. 2011;6(3):369–89.CrossRefPubMed

15.

Hashimoto H, Ikegami N, Shibuya K, Izumida N, Noguchi H, Yasunaga H, Miyata H, Acuin JM, Reich MR. Cost containment and quality of care in Japan: Is there a trade-off? Lancet. 2011;378(9797):1174–82.CrossRefPubMed

16.

The Lancet Oncology. Generic drugs: are they the future for affordable medicine? Lancet Oncol. 2018;19(2):149. https://doi.org/10.1016/S1470-2045(18)30033-0.CrossRefPubMed

17.

Kawaura A, Croix SJL. Japan’s shift from process to product patents in the pharmaceutical industry an event study of the impact on Japanese firms. Econ Inquiry. 1995;33(1):88–103.CrossRef

18.

Sakakibara M, Branstetter LG. Do stronger patents induce more innovation? Evidence from the 1988 Japanese patent law reforms; 1999.

19.

Masuda S. The market exclusivity period for new drugs in Japan: overview of intellectual property protection and related regulations. J Generic Med. 2008;5(2):121–30.CrossRef

Title: Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
Authors: Makoto Kosaka
Akihiko Ozaki
Yudai Kaneda
Hiroaki Saito
Erika Yamashita
Anju Murayama
Hanano Mamada
Tetsuya Tanimoto
Mihajlo Jakovljevic
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: Cost Effectiveness and Resource Allocation / Issue 1/2023
Electronic ISSN: 1478-7547
DOI: https://doi.org/10.1186/s12962-023-00441-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Clinical and economic benefits of image-guided system in functional endoscopicsinus surgery: a retrospective chart review study in China

Cost-effectiveness thresholds or decision-making threshold: a novel perspective

Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer

Essential emergency and critical care as a health system response to critical illness and the COVID19 pandemic: what does it cost?

Factor associated with willingness to pay for prevention of cancer: a study of prostate cancer screening

The impact of government subsidy programs on equity in health financing